In this study, we showed that blockade of host VEGFR1 or VEGFR2 by using the species-specific neutralizing antibodies could suppress ESCC tumor growth, angiogenesis and metastasis in preclinical models, thus providing strong evidence of the importance of tumor micro- and systemic environments in cancer progression. The gene discussed is FLT1; the disease is esophageal squamous cell carcinoma.